Pfenex Inc. Information Request Form

Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of Pfenex Inc. (“Pfenex” or the “Company”) (NYSE: PFNX) to Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) (“Ligand”). Under the terms of the merger, Ligand will acquire all outstanding shares of Pfenex for $12.00 per share in cash.

The Pfenex merger investigation concerns whether the Board of Pfenex has harmed stockholders by agreeing to enter into this transaction and whether all material facts have been properly disclosed to stockholders.